Through our unique approach to gene science based on Nobel Prize-winning technology, we are moving forward rapidly to bring innovative therapies to market.
We have advanced multiple drug candidates into clinical development. We are presently devoting most of our resources to the development and commercialization of our two most advanced drug candidates, telotristat ethyl for carcinoid syndrome diarrhea and sotagliflozin for type 1 and type 2 diabetes. We have also advanced a number of additional compounds into various stages of clinical and preclinical development.
Sotagliflozin, or LX4211, is an orally-delivered small molecule compound that we are developing for the treatment of type 1 and type 2 diabetes mellitus. Sotagliflozin was internally generated by our medicinal chemists and inhibits both sodium-glucose cotransporter type 2, or SGLT2, a transporter responsible for most of the glucose reabsorption performed by the kidney, and sodium-glucose cotransporter type 1, or SGLT1, a transporter responsible for glucose and galactose absorption in the gastrointestinal tract. Our scientists identified mice lacking SGLT1, SGLT2 or both as having potent anti-diabetic phenotypes across multiple measures of glucose control and metabolism, and found that compounds inhibiting both targets had a favorable preclinical profile relative to compounds selective for SGLT2.
LXRX - Pipeline Progress
|Program||Target||Area of Research||Pre-Clinical||Phase I||Phase II||Phase III||Regulatory Review||Regulatory Approval|
|Telotristat ethyl (LX1606)||TPH1||Carcinoid Syndrome Diarrhea||
||Approved in the United States|
|Sotagliflozin (LX4211)||SGLT1/SGLT2||Type 1 Diabetes||
|Sotagliflozin (LX4211)||SGLT1/SGLT2||Type 2 Diabetes||
|LX2761||SGLT1 (GI tract)||Diabetes||